JosephPHorriganMDFAACAP

Psychiatry • Research Triangle Park, NC

Child & Adolescent Psychiatry

Physician

Join to view full profile

Dr. Horrigan is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Horrigan's full profile

Already have an account?

Office
Five Moore Drive
Research Triangle Park, NC 27709
Phone+1 919-483-7942

Fax+1 919-483-8302

Education & Training

University of North Carolina HospitalsFellowship, Child and Adolescent Psychiatry, 1991 - 1994
University of North Carolina HospitalsResidency, Psychiatry, 1988 - 1991
University of Rochester School of Medicine and DentistryClass of 1988

Certifications & Licensure

CA State Medical License 1998 - 2026
ME State Medical License 2021 - 2026
MA State Medical License 1994 - 2025
NC State Medical License 1990 - 2025
RI State Medical License 1999 - 1999
American Board of Psychiatry and Neurology Psychiatry
American Board of Psychiatry and Neurology Child & Adolescent Psychiatry

Clinical Trials

Study of NNZ-2566 in Patients With Traumatic Brain Injury Start of enrollment: 2010 Apr 01
Completed
Phase 2
Study of NNZ-2566 in Patients With Traumatic Brain Injury Under EFIC Start of enrollment: 2013 Feb 01
Completed
Phase 2
A Safety Study of NNZ-2566 in Patients With Rett Syndrome Start of enrollment: 2013 Mar 01
Completed
Phase 2
A Safety Study of NNZ-2566 in Patients With Fragile X Syndrome Start of enrollment: 2014 Jan 01
Completed
Phase 2
A Safety and Efficacy Study of NNZ-2566 in Patients With Mild Traumatic Brain Injury (mTBI) Start of enrollment: 2014 Sep 01
Terminated
Phase 2
Study of Tideglusib in Adolescent and Adult Patients With Myotonic Dystrophy Start of enrollment: 2016 Jul 20
Completed
Phase 2
Efficacy and Safety of Tideglusib in Congenital Myotonic Dystrophy Start of enrollment: 2021 Mar 03
Completed
Phase 2, Phase 3
hCT-MSC in Children With Autism Spectrum Disorder Start of enrollment: 2020 Oct 12
Completed
Phase 2
Join now to see all

Publications & Presentations

PubMed

International workshop: what is needed to ensure outcome measures for Rett syndrome are fit-for-purpose for clinical trials? June 7, 2023, Nashville, USA.
Jenny Downs, Dominique C Pichard, Walter E Kaufmann, Joseph P Horrigan, Melissa Raspa
Trials. 2024-12-21
An open-label study evaluating the safety and efficacy of AMO-01 for the treatment of seizures in Phelan-McDermid syndrome.
Tess Levy, J Lloyd Holder Jr, Joseph P Horrigan, Michael F Snape, Alison McMorn
HGG Advances. 2024-12-16
1 citations
Ensuring Stakeholder Feedback in the Design and Conduct of Clinical Trials for Rare Diseases: ISCTM Position Paper of the Orphan Disease Working Group.
Gahan J Pandina, Joan Busner, Lucas Kempf, Joan Fallon, Larry D Alphs
Innovations in Clinical Neuroscience. 2024-03-01

Press Mentions

AMO Pharma Announces Expansion of Pivotal REACH-CDM Study in Congenital Myotonic DystrophyDecember 22nd, 2021
AMO Pharma Announces Activation of Additional Clinical Trial Sites for Pivotal REACH-CDM Study in Congenital Myotonic DystrophyMay 17th, 2021
AMO Pharma to Participate in Myotonic Dystrophy Foundation "Meet the DM Drug Developers" Program on March 5, 2021March 3rd, 2021
Join now to see all

Professional Memberships

American Psychiatric Association - APA
Fellow
American Academy of Child and Adolescent Psychiatry - AACAP
Fellow
American Medical Association - AMA
Member
American Neuropsychiatric Association - ANPA
Member
International Society for Autism Research
Member

Other Languages

Spanish